![Slideshow of doctors](/sites/default/files/2022-01/heros-eu.gif)
GORE® VIABAHN® Device family
Join the next generation of care in the treatment of aortoiliac occlusive disease
The latest generation of covered stent grafts
GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis (VBX Stent Graft)
GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface* (GORE® VIABAHN® Device)
VBX Stent Graft
Decide with data
Five-year follow-up shows the VBX Stent Graft continues to be a long-term durable treatment option for complex aortoiliac occlusive disease (AIOD).1
The Gore VBX FLEX Clinical Study three-year follow-up found the VBX Stent Graft to be a robust and durable treatment option for AIOD.2 Now, sustained patient benefit and durability are demonstrated through five years.
Physician-initiated five-year VBX Stent Graft follow-up
Objective and methodology1
- This physician-initiated study enrolled 59 of the initial 134 patients from three participating centers that were representative of the VBX FLEX Study three-year follow-up cohort. 28 patients completed the five-year follow-up.
- The primary durability endpoint was long-term primary patency.
DURABLE CLINICAL OUTCOMES THROUGH FIVE YEARS1:
![89.5%](/sites/default/files/styles/max_750x750/public/2023-04/DX-Studio-VBX-VSX-By-data-1_0.jpg.webp?itok=PvzO4MT-)
primary patency per lesion
![96.1%](/sites/default/files/styles/max_750x750/public/2023-04/DX-Studio-VBX-VSX-By-data-2_0.jpg.webp?itok=6xNqfTD_)
primary assisted patency per lesion
![89.1%](/sites/default/files/styles/max_750x750/public/2023-04/DX-Studio-VBX-VSX-By-data-3_0.jpg.webp?itok=xBdnV1zS)
freedom from target lesion revascularization per subject
SUSTAINED PATIENT BENEFIT THROUGH FIVE YEARS1:
![89%](/sites/default/files/styles/max_750x750/public/2023-04/DX-Studio-VBX-VSX-By-data-4_0.jpg.webp?itok=Vep83CyA)
of patients improved ≥ 1 Rutherford category from baseline
![.15](/sites/default/files/styles/max_750x750/public/2023-04/DX-Studio-VBX-VSX-By-data-5_0.jpg.webp?itok=DqiPJ1-E)
improvement in mean resting ankle-brachial index (ABI)
(P < .001, .95 mean ABI) †
![3x](/sites/default/files/styles/max_750x750/public/2023-04/DX-Studio-VBX-VSX-By-data-6_0.jpg.webp?itok=t0gV_yfo)
improvement in median WIQ measures
The case for long-term durable clinical outcomes:
Case study 1: Restoring flow to a patient with stenosis at the aortoiliac bifurcation
Case study 2: Restoring flow in a patient with severe claudication and focal iliac calcification
GORE® VIABAHN® Device
Durable clinical outcomes and proven patency in complex cases.
![VIABAHN® Device](/sites/default/files/styles/max_750x750/public/2021-04/AZ0854-EN1-VSX-5409-FNL-OL-1000x189.png.webp?itok=lb6EeFnM)
GORE® VIABAHN® Device outcomes in iliac occlusive disease
Retrospective multicenter study, evaluating the performance of the GORE® VIABAHN® Device (n = 93) for the treatment of external iliac artery obstructive disease.
![89.8%](/sites/default/files/styles/max_750x750/public/2023-05/23966300-VBX-Study-Pie-Charts-89-8.jpg.webp?itok=1U1GlRB5)
Primary patency at 42 months3
![91%](/sites/default/files/styles/max_750x750/public/2023-05/23966300-VBX-Study-Pie-Charts-91.jpg.webp?itok=By_dQE9I)
Secondary patency at 42 months3
![94.6%](/sites/default/files/styles/max_750x750/public/2023-05/23966300-VBX-Study-Pie-Charts-94-6_0.jpg.webp?itok=SuRW3plW)
Limb salvage rate at 42 months3
*As used by Gore, PROPATEN Bioactive Surface refers to Gore’s proprietary CBAS® Heparin Surface.
†(P < .001) Statistically significant change from pre-procedure.
- Holden A, Takele E, Hill A, et al. Long-Term Follow-up of Subjects With Iliac Occlusive Disease Treated With the Viabahn VBX Balloon-Expandable Endoprosthesis. Journal of Endovascular Therapy. 2023;0(0). doi:10.1177/15266028231165723.
- Panneton JM, Bismuth J, Gray BH, Holden A. Three-year follow-up of patients with iliac occlusive disease treated with the Viabahn Balloon-Expandable Endoprosthesis. Journal of Endovascular Therapy 2020;27(5):728-736.
- Squizzato, F., Mosquera-Rey, V., Zanabili Al-Sibbai, A. et al. Outcomes of Self-Expanding Covered Stents for the Treatment of External ILIAC Artery Obstructive Disease. Cardiovasc Intervent Radiol 46, 579–587 (2023). https://doi.org/10.1007/s00270-023-03370-9
Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. RXOnly
CBAS is a trademark of Carmeda AB, a wholly owned subsidiary of W. L. Gore & Associates, Inc
23959700-EN